Cancer Biology

1250 Cell-Membrane-Derived Nanoparticles with Notch-1 Suppressor Delivery Promote Hypoxic Cell–Cell Packing and Inhibit Angiogenesis Acting as a Two-Edged Sword.

1249 BRCA1/Trp53 heterozygosity and replication stress drive esophageal cancer development in a mouse model.

1248 Interventional real-time optical imaging guidance for complete tumor ablation.

1247 High-risk human papillomavirus-18 uses an mRNA sequence to synthesize oncoprotein E6 in tumors.

1246 Compromised nuclear envelope integrity drives TREX1-dependent DNA damage and tumor cell invasion.

1245 Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis.

1244 A protein interaction landscape of breast cancer.

1243 A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity.

1242 Tetraspanin 6 is a regulator of carcinogenesis in colorectal cancer.

1241 A robust, cost-effective technique based on whole-exome sequencing data can be used to characterize immune infiltrates, relate the extent of these infiltrates to somatic changes in tumours, and enables prediction of tumour responses to immune checkpoint inhibition therapy.

1240 Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis.

1239 The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation.

1238 Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models.

1237 A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models.

1236 Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.

1235 METTL14 facilitates global genome repair and suppresses skin tumorigenesis.

1234 Cycling cancer persister cells arise from lineages with distinct programs.

1233 A new computational approach to in silico mutagenesis screening allow comprehensive mapping of cancer driver mutations.

1232 Drivers and suppressors of triple-negative breast cancer.

1231 Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.

Free Images for Presentation: sunipix SUNIPIX